Article, see p 604 P atients with concomitant stable coronary artery disease (CAD) and atrial fibrillation (AF) are at high risk of both ischemic and bleeding events, and are frequently encountered in daily practice because 30% of patients with AF also have CAD and up to 15% of patients with stable CAD have concomitant AF. [1] [2] [3] [4] [5] [6] In this setting, it is crucial to identify the antithrombotic regimen with the optimal benefit/risk ratio to be pursued lifelong. Theoretically, these specific patients may require a dual antithrombotic regimen combining oral anticoagulation and single antiplatelet therapy to avoid systemic embolism and stroke, on the one hand, and recurrent coronary and vascular events on the other. However, based on observational data, 3, 4, 7, 8 current guidelines and expert consensus recommend using oral anticoagulation alone as the default strategy to limit the risk of bleeding in such patients.
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atients with concomitant stable coronary artery disease (CAD) and atrial fibrillation (AF) are at high risk of both ischemic and bleeding events, and are frequently encountered in daily practice because 30% of patients with AF also have CAD and up to 15% of patients with stable CAD have concomitant AF. [1] [2] [3] [4] [5] [6] In this setting, it is crucial to identify the antithrombotic regimen with the optimal benefit/risk ratio to be pursued lifelong. Theoretically, these specific patients may require a dual antithrombotic regimen combining oral anticoagulation and single antiplatelet therapy to avoid systemic embolism and stroke, on the one hand, and recurrent coronary and vascular events on the other. However, based on observational data, 3, 4, 7, 8 current guidelines and expert consensus recommend using oral anticoagulation alone as the default strategy to limit the risk of bleeding in such patients. [9] [10] [11] Indeed, most observational studies suggest that the combination of single antiplatelet therapy and oral anticoagulation is associated with a higher risk of bleeding without a clear benefit on ischemic end points. 3, 4, 7, 8 However, it should be emphasized, first, that this literature is sparse, and, second, that these observational studies suffer from biases. Most are registry retrospective analyses; the use of single antiplatelet therapy in addition to oral anticoagulation was not allocated randomly; and important confounders may not have been properly accounted for. Patients who received single antiplatelet therapy on top of oral anticoagulation at inclusion are likely to be at higher risk of ischemic events in comparison with those under oral anticoagulation alone, therefore limiting the possibility to show a benefit of this strategy over oral anticoagulation alone. Finally, in most studies, the antithrombotic regimen was only collected at inclusion, and neither the changes during follow-up nor the exact antithrombotic regimen that was really taken by the patient at the time of incident ischemic or bleeding events was collected. Randomized trials are therefore direly needed in this context. In this issue, Matsumura-Nakano et al 12 report the results of the OAC-ALONE trial (Optimizing Antithrombotic Care in Patients With Atrial Fibrillation and Coronary Stent), the first randomized trial in the field. The authors should be congratulated for addressing this issue head on in a randomized trial.
The OAC-ALONE trial tested the hypothesis that oral anticoagulation alone is noninferior to the combination of single antiplatelet therapy and oral anticoagulation. 12 This open-label randomized trial started in 2013 in Japan and planned to enroll 2000 patients with stable CAD (at least 1 year after the last acute coronary event, median interval from the last percutaneous coronary intervention to study enrollment of 4.5 years) and concomitant AF who were receiving dual antithrombotic therapy (single antiplatelet therapy and oral anticoagulation) at the time of inclusion to test whether patients should continue or stop sin-gle antiplatelet therapy. The initial planned follow-up was 18 months. The primary end point was a composite of all-cause death, myocardial infarction, any stroke (ischemic or hemorrhagic), or systemic embolism. Unfortunately, the trial could not answer the initial question essentially because of small sample size. The study was terminated on December 31, 2016 because of slow patient enrollment and eventually included only 690 patients through a 38-month period of inclusion. The trial therefore suffers from the lack of power, and noninferiority was not established even though a large noninferiority margin had been chosen (50% increase risk in the primary end point; hazard ratio, 1.5). The rate of the primary end point was 15.7% in the oral anticoagulation alone group and 13.6% in the dual therapy group (hazard ratio, 1.16; [0.79-1.72]; P=0.20 for noninferiority; P=0.45 for superiority). Among secondary end points, a statistically nonsignificant 17% reduction of the composite ischemic end point (cardiovascular death, myocardial infarction, ischemic stroke, or systemic embolism) and a statistically nonsignificant 27% increase in International Society on Thrombosis and Haemostasis major bleeding were seen in the dual therapy group in comparison with the oral anticoagulation alone group. These tantalizing observations do not settle the issue of which strategy should be considered as default in clinical practice (and for which patients) but will be useful in planning future trials.
Of note, some limitations of the OAC-ALONE trial should be emphasized. First, the open-label design and the absence of placebo led to substantial differences in the intensity of oral anticoagulation between the 2 groups. In fact, the dual therapy group (single antiplatelet therapy and oral anticoagulation) received a lower dose of anticoagulants, either vitamin K antagonists (less intensive international normalized ratio control) or direct oral anticoagulants, in comparison with the oral anticoagulation alone group, and this may have impacted safety, efficacy, or both in that treatment arm. Second, there was close to a 10% crossover rate to the alternative antithrombotic regimen in both groups, which had not been anticipated and may have further decreased the power of the study. Finally, the majority of patients received warfarin as the oral anticoagulant, even though currently many patients receive direct oral anticoagulants, and it has been documented that the use of direct oral anticoagulants instead of warfarin may allow a reduction of the rate of bleeding, in particular, intracranial hemorrhage. 13 The question of whether single antiplatelet therapy should be added to oral anticoagulation in patients with stable CAD and AF remains unsettled. Further adequately powered trials are therefore warranted. Ideally, they should be randomized, double-blind, placebocontrolled trials to avoid differences in anticoagulation intensity between groups (especially lower anticoagulation in the dual therapy group). In addition, it might be relevant to target patients at high risk of ischemic events (post-acute coronary syndrome, diabetes mellitus, or complex percutaneous coronary intervention) and low risk of bleeding to definitively test whether dual therapy is beneficial in some patients with concomitant stable CAD and AF. Patients at high risk of bleeding were not excluded from the OAC-ALONE trial. Finally, such a trial could include patients either receiving dual therapy (single antiplatelet therapy and oral anticoagulation) or anticoagulation alone at the time of inclusion, and not only patients on dual therapy as it was done in the present study. Patients under dual therapy could be tested to continue or stop single antiplatelet therapy, and patients under oral anticoagulation alone could be tested to restart or not single antiplatelet therapy. This might (1) facilitate recruitment and (2) 
Disclosures
Dr Lemesle reports personal fees for lectures or consulting from Amgen, AstraZeneca, Bayer, Biopharma, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, MSD, Pfizer, Sanofi, Servier, and The Medicines Company, outside the submitted work.
